FDA plans to only issue pediatric exclusivity for new studies — not just those required under PREA
The FDA is scaling back when it will grant up to two 6-month periods of exclusivity to pharma sponsors once they complete FDA-mandated written requests …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
